Breath-holding spells. Other and unspecified abnormalities of breathing
Conditions
Interventions
Intervention 1: Intervention group: administration of piracetam in 2 mounth period with dose of 40/mg/kg/day. Intervention 2: contorol group: administration of placebo in 2 mounth period.
Treatment - Drugs
Placebo
Intervention group: administration of piracetam in 2 mounth period with dose of 40/mg/kg/day
contorol group: administration of placebo in 2 mounth period
Sponsors
Mazandaran University of Medical Sciences and Health Services
Eligibility
Sex/Gender
All
Age
1 Years to 3 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: 1) History of breath- Holding spell and physical and neurological examination by pediatric neurologist. 2) Minimum age 6 month and maximum 3 years old 3) Normal EEG 4) absent of systematic disease 5) Normal growth and Development 6) No history of epilepsy in family member 7) No Electrolyte Abnormality (Hypoglycemia and Hypocalcaemia ) Exclusion criteria: 1) Children with history of convulsion 2) Children that received Anticonvulsant drugs. 3) Delayed neurotic development 4) all Children with heart diseases 5) all children with anemia 6) Side effects of priacetam including true dizziness, convulsion, extra pyramidal sings, lethargy, headache, sleepy; gastrointestinal complication including nausea and vomiting, diarrhea, constipation, anorexia, increased weight
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The number of Breath-holding spell. Timepoint: before prevention and 2 weeks after prevention. Method of measurement: questionarie of parents. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactMotahareh kheradmand
Mazandaran Univercity of Medical sciences and Health ervices
Outcome results
None listed